Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 62Carcinoma, Hepatocellular 25Neoplasm Metastasis 15Rectal Neoplasms 11Colonic Neoplasms 10Gastrointestinal Stromal Tumors 9Sarcoma 6Ovarian Neoplasms 5Osteosarcoma 5Glioblastoma 5Cholangiocarcinoma 5Stomach Neoplasms 4Melanoma 4Liver Neoplasms 4Sarcoma, Ewing 3Pancreatic Neoplasms 3Neoplasms 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Rhabdomyosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Hemangiosarcoma 2Gastrointestinal Neoplasms 2

Interventions

Capecitabine 6Irinotecan 5Fluorouracil 5Cisplatin 5Oxaliplatin 4Leucovorin 4Gemcitabine 4apatinib 3Sorafenib 3Bevacizumab 3tislelizumab 2pembrolizumab 2Sunitinib 2Radiotherapy 2Paclitaxel 2Immune Checkpoint Inhibitors 2Cyclophosphamide 2Cetuximab 2Aspirin 2Ascorbic Acid 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1regorafenib 1pyrotinib 1pemigatinib 1lutetium Lu 177 dotatate 1huachansu 1halofantrine 1guadecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Digestive System Neoplasms × regorafenib × Clear all
NCT06099821 2023-10-26

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
39 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡